tiprankstipranks
Trending News
More News >
Needham healthcare analysts hold analyst/industry conference call
PremiumThe FlyNeedham healthcare analysts hold analyst/industry conference call
25d ago
Apellis price target raised to $31 from $30 at Scotiabank
Premium
The Fly
Apellis price target raised to $31 from $30 at Scotiabank
26d ago
Promising Outlook for Apellis Pharmaceuticals: Buy Rating Backed by Key Milestones and Attractive Valuation
Premium
Ratings
Promising Outlook for Apellis Pharmaceuticals: Buy Rating Backed by Key Milestones and Attractive Valuation
26d ago
Buy Rating for Apellis Pharmaceuticals Driven by Empaveli’s Market Potential and Efficacy in C3G Treatment
PremiumRatingsBuy Rating for Apellis Pharmaceuticals Driven by Empaveli’s Market Potential and Efficacy in C3G Treatment
1M ago
JPMorgan healthcare analysts hold an analyst/industry conference call
Premium
The Fly
JPMorgan healthcare analysts hold an analyst/industry conference call
1M ago
Apellis price target raised to $54 from $50 at JPMorgan
Premium
The Fly
Apellis price target raised to $54 from $50 at JPMorgan
2M ago
Buy Rating for Apellis Pharmaceuticals Driven by Strategic Growth Initiatives and Strong Product Performance
PremiumRatingsBuy Rating for Apellis Pharmaceuticals Driven by Strategic Growth Initiatives and Strong Product Performance
2M ago
Hold Rating for Apellis Pharmaceuticals Amidst Market Challenges and Moderate Growth Expectations
Premium
Ratings
Hold Rating for Apellis Pharmaceuticals Amidst Market Challenges and Moderate Growth Expectations
2M ago
Apellis Pharmaceuticals Faces Financial Challenges Amid Ambitious Drug Commercialization Efforts
Premium
Company Announcements
Apellis Pharmaceuticals Faces Financial Challenges Amid Ambitious Drug Commercialization Efforts
2M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100